1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse ...
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months) 2. ...
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in Clinical Cancer Research.
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...
1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor inhibitor, in addition to standard therapy demonstrated longer overall survival ...
Click to read this study in the European Journal of Cancer.
Click to read this study in the European Journal of Cancer.
